PharMerica (NYSE: PMC) reported earnings on Nov. 1. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Sep. 30 (Q3), PharMerica met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue dropped and GAAP earnings per share grew significantly.

Gross margins increased, operating margins dropped, net margins grew.

Revenue details
PharMerica reported revenue of $442.0 million. The eight analysts polled by S&P Capital IQ predicted a top line of $446.4 million on the same basis. GAAP reported sales were 15% lower than the prior-year quarter's $518.7 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.33. The nine earnings estimates compiled by S&P Capital IQ predicted $0.30 per share. GAAP EPS of $0.20 for Q3 were 25% higher than the prior-year quarter's $0.16 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 17.1%, 270 basis points better than the prior-year quarter. Operating margin was 2.8%, 60 basis points worse than the prior-year quarter. Net margin was 1.4%, 50 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $434.9 million. On the bottom line, the average EPS estimate is $0.30.

Next year's average estimate for revenue is $1.84 billion. The average EPS estimate is $1.22.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 122 members out of 127 rating the stock outperform, and five members rating it underperform. Among 20 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 18 give PharMerica a green thumbs-up, and two give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on PharMerica is outperform, with an average price target of $14.79.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.